← Sage — Cardiology · Sage hub

Sage — The Metabolic Hypothesis of Nitric Oxide

Sage

Hypothesis language only — not a nitrate/PDE5 protocol, not a blood-pressure drug holiday, not an erectile self-treatment guide. Do not start, stop, or combine nitrates, PDE5 inhibitors, or other vasoactive drugs from this page. Education only; no Rx advice.

Nitric Oxide as Energy Flux Manager: Matching Delivery, Consumption, and Maintenance to Mitochondrial Demand

This essay presents a metabolic and evolutionary hypothesis for educational and philosophical purposes. It is not medical advice, diagnosis, or treatment. Individual circumstances vary; readers should consult a qualified clinician before making significant changes to diet, lifestyle, or medications, especially if they have existing medical conditions or take nitrates or other vasoactive drugs.

The remainder of biology revolves around a simple toll-keeper. Food electrons descend the mitochondrial electron transport chain in stepwise redox reactions. Energy extracted along that descent powers proton pumps. The resulting chemiosmotic force drives protons back through ATP synthase, which collects a toll of roughly three ATP for each full turn of its proton-driven rotor. Everything that looks like "physiology"---vascular tone, muscle work, immune restraint, erectile hemodynamics, plaque biology, intraocular pressure, axonal transport at the lamina cribrosa---is downstream of whether that toll-keeper is supplied with oxygen, reducing equivalents, and an intact membrane, and whether the ATP so collected is sufficient for the load the tissue is asked to carry.

Nitric oxide is conventionally taught as a vasodilator. That description is true and incomplete. NO is better understood as an energy-flux manager: a short-lived gas that simultaneously adjusts delivery of oxygen and substrate to working mitochondria, rations consumption of oxygen at cytochrome c oxidase so proximal organelles do not steal the entire gradient, and protects the conduit so that future flux is not obstructed by adhesion, thrombosis, and smooth-muscle overgrowth. When NO bioavailability is adequate and coupled, high energy flux is possible without proportional damage. When it is lost, the cell experiences a delivery-and-matching failure that the mitochondrial-metabolic hypotheses of aging and cancer already identify as upstream: chronic mismatch between ATP supply and maintenance demand.

The same gas writes a second chapter that this revision makes explicit. Acute NO-driven matching is hormesis: a pulsed, reversible increase in conductance that meets a load. Left on as the standing operating procedure, the same loops remodel tissue and reset set-points. Plaque, a stiff artery, a failed erection, a glaucomatous field, insulin resistance, some dementia, and the locked-in glycolytic clone of cancer are not random multifactorial decorations. They are scars of matching programs used as architecture. Hypertension belongs in that list, with the extra complexity that the scar is cross-system---endothelium, resistance artery, conduit wall, sympathetic tone, and kidney---without that complexity diminishing the root.

This essay gathers the nitric oxide--cGMP--PDE5 axis, the difference between vascular smooth muscle and skeletal muscle, shear-stress matching of flow to load, cytochrome oxidase inhibition, the initiating role of NO loss in atherosclerosis, the true nature of vasculogenic erectile failure, the limits of PDE5 inhibitors as prevention, the distinct ocular effects of the drug class, the acute-versus-chronic grammar of compensation, the scar framework that unifies plaque, pressure, field loss, and tolerance, and the three-compartment role of NO in glaucoma---and places all of them inside one variable: net ATP output relative to demand, managed at the interface between blood and mitochondrion.

Where the Vasodilator Story Falls Short

The textbook cascade is correct as far as it goes. Endothelial nitric oxide synthase oxidizes L-arginine to NO. NO diffuses into adjacent vascular smooth muscle, activates soluble guanylate cyclase, raises cGMP, activates protein kinase G, lowers cytosolic calcium, and relaxes the cell. Phosphodiesterase type 5 hydrolyzes cGMP and terminates the signal. PDE5 inhibitors prolong whatever cGMP the existing NO pulse produced. They do not manufacture nitric oxide. They amplify a signal that must already exist.

That account explains why sildenafil works in the corpus cavernosum after sexual stimulation supplies nNOS- and eNOS-derived NO, and why it fails when the upstream pulse is gone. It does not explain why endothelial NO loss is among the earliest detectable events in atherogenesis, why erectile failure so often precedes coronary symptoms, why NO modestly inhibits mitochondrial respiration, why laminar shear is anti-atherogenic while oscillatory shear is not, why an EnSurf-optimized adult already running high flux may gain little from chronic PDE5 blockade, why exercise raises pressure while muscle resistance falls, or why the conventional outflow pathway of the eye runs a shear--eNOS barostat that is almost a copy of the arterial one.

The missing layer is energetic. Vessels exist to deliver the two substrates the toll-keeper cannot do without: oxygen as the terminal electron acceptor, and metabolic fuel as the source of high-energy electrons. NO is the local language in which demand, delivery, and consumption are negotiated. Treating it only as a blood-pressure gadget is the same category error as treating aging as "oxidative damage" or cancer as "mutations first." Those phenomena are real. They are not the engine.

The Metabolic Hypothesis

Nitric oxide is a flux-matching gas whose physiologic job is to keep mitochondrial ATP generation aligned with tissue load.

It does this in three coordinated acts.

Act I --- Delivery. Working tissue opens downstream arterioles. Flow through the parent artery rises. Laminar wall shear is transduced by endothelial mechanosensors (PIEZO1, the glycocalyx, integrins, purinergic receptors after ATP release) into calcium entry and eNOS phosphorylation. More NO is made. Feed arteries dilate. Perfusion pressure is preserved while the microcirculation is open. The tree scales together instead of the smallest vessels dumping pressure. Over hours to days the same shear writes more eNOS (KLF2 and related programs). Regular high energy flux---training---is therefore not merely calorie expenditure. It is the chronic instruction that keeps the delivery system competent.

Local metabolic and redox signals start the opening. Potassium, adenosine, protons, and muscle nNOS contribute. One proposed error-signal model holds that when oxygen and substrate delivery are adequate, interstitial superoxide from NAD(P)H oxidases quenches NO before it reaches arteriolar smooth muscle. When mitochondria begin to consume oxygen and reducing equivalents, that superoxide emission falls, more NO survives the interstitium, and the arteriole opens. In that model, demand is reported as the withdrawal of an inhibitor of NO, not only as the secretion of a new dilator. Once flow rises, shear recruits the upstream endothelium and the match becomes organism-scale.

Act II --- Rationing. The same NO that opened the vessel binds cytochrome c oxidase, complex IV, the last enzyme before oxygen becomes water. Binding is dual: competitive with oxygen at reduced heme a3, and reactive at oxidized CuB with conversion toward nitrite. At the nanomolar concentrations produced by eNOS and nNOS, inhibition is partial and reversible. Cells nearest the capillary see the highest NO and consume oxygen a little more slowly. Oxygen is spared to diffuse farther into the tissue. Respiration becomes more sensitive to local PO2. On this hypothesis, state-3 respiration (ADP present, ATP being made, load high) is more NO-sensitive than state-4, so the brake is stronger precisely when mitochondria are working hard---until flow and local oxygen are restored.

This is not poisoning the engine. It may prevent the first mitochondria along the oxygen gradient from monopolizing the terminal acceptor. Delivery and rationing are one system. Increase flow and slightly throttle proximal consumption, and deep tissue can still run oxidative phosphorylation.

Act III --- Conduit protection. The same low-flux, eNOS-derived NO that matches acute load also keeps the pipe from remodeling into an obstruction. It restrains leukocyte adhesion (VCAM-1, ICAM-1, P-selectin, MCP-1), platelet aggregation, endothelial permeability and lipoprotein influx, and vascular smooth-muscle proliferation and migration. A lumen that stays clean is a lumen that can still deliver electrons' destination and fuel. Loss of this tonic anti-atherogenic tone is why NO sits at the beginning of plaque biology rather than at its end.

When these three acts run, energy flux can be high: more substrate in, more oxygen appropriately distributed, more ATP out, less need for glycolytic rescue, less mtDAMP-driven inflammation. When they fail, the cell faces the same upstream deficit named in the metabolic hypotheses of aging and cancer---insufficient oxidative ATP relative to the cost of remaining ordered.

Smooth Muscle Is the Valve; Skeletal Muscle Is the Load

Confusion between muscle types has muddied this field for decades.

Vascular smooth muscle is the effector of the NO--cGMP--PDE5 valve. Tone in arterioles, feed arteries, and cavernosal trabeculae is set by cytosolic calcium and the phosphorylation state of the contractile apparatus. cGMP and PKG lower that calcium and relax the cell. PDE5 is abundant in these tissues precisely because the signal must be terminable. This is why PDE5 inhibitors have their clearest clinical effect in corpus cavernosum and pulmonary arterioles. Trabecular meshwork cells are the same family of effector: smooth-muscle-like, cGMP-relaxable, sitting in a shear field.

Skeletal muscle fibers are the load. Their contraction is actin--myosin, troponin, sarcoplasmic reticulum calcium---not the cGMP valve. They do express nNOS, especially in fast-twitch fibers, localized at the sarcolemma with dystrophin. Fiber-derived NO may modestly aid local hyperemia and glucose uptake, and in rat muscle it restrains force via cGMP. It is a modulator of the engine and a contributor to local matching, not the primary controller of fiber shortening.

Exercise hyperemia in skeletal muscle is therefore redundant by design. Metabolites, the muscle pump, prostaglandins, endothelium-derived hyperpolarization, and neural inputs all participate. Blocking NOS reduces resting flow more consistently than it abolishes the large rise in flow during work. NO is necessary for elegant matching and for feed-artery coordination. It is not the sole permission slip for muscle perfusion. That redundancy is what high energy flux requires: the ability to raise delivery an order of magnitude without depending on a single molecule.

The practical distinction is simple. When we speak of "NO regulating vascular flow," we mean smooth muscle in the wall of the vessel that feeds the mitochondrion. When we speak of "NO in skeletal muscle," we mean a fiber-autocrine and local-vascular signal sitting on top of a contraction mechanism that does not itself run on cGMP.

Acute Matching: Ohm's Law During the Good Compensation

Mean arterial pressure is cardiac output times total peripheral resistance. In the electrical analogy, V = I × R. During exercise the terms move in opposite directions, and that is the point.

Working muscle accumulates metabolites and NO. Arteriolar resistance in that bed falls. Total peripheral resistance falls with it, though visceral and inactive beds constrict under sympathetic drive and so the whole-body drop in TPR is less than the local drop in the working muscle. Cardiac output rises several-fold: heart rate, stroke volume, muscle pump, venoconstriction of capacitance beds, and central command. Because the rise in flow exceeds the fall in resistance, systolic pressure and usually MAP rise even while the working muscle is dilated. Flow to that muscle can increase an order of magnitude. The pressure rise is the residual of driving a large current through a still-finite arterial tree. It is not the purpose of the act. The purpose is delivery.

That is hormesis and good compensation. The mismatch---load above current homeostatic output---is brief. NO and metabolites open conductance. The heart fills the open bed. After the bout, conductance stays high for a while and pressure often falls (post-exercise hypotension). Repeated bouts write more eNOS and more mitochondrial volume. The next mismatch is smaller relative to capacity.

Two errors follow if this physiology is misread. The first is to treat the exercise pressure rise as "hypertension doing its job," as if high cuff pressure were the matching variable. Flow is the matching variable. Pressure is what is left when current and resistance have moved. The second is to treat chronic hypertension as the same act left running. It is not. In healthy exercise, resistance in the working bed falls and flow soars. In established essential hypertension, resistance is high and cardiac output is normal or low. You are paying a pressure tax without buying proportional tissue perfusion. That is failed matching, not completed compensation.

Chronic Operating Procedure and the Scar

A scar, in this model, is locked-in tissue and set-point change after a compensatory loop has been running outside the window natural selection built it for.

Acute loop: mismatch detected → short-acting signals (NO, insulin, sympathetic drive, glycolysis, trabecular shear--eNOS, cavernosal nNOS) → restore ATP supply or dump load → signal turns off.

Chronic loop: mismatch never clears → the same signals stay high, or the wall and parenchyma remodel around them → the remodeling is the new physiology → the high signal is now required just to stand still, and the remodeling itself creates new mismatch.

In this model, the Crabtree and Warburg effects mark the two ends of this path inside the cell. The Crabtree effect is acute and reversible: oxidative phosphorylation is suppressed while metabolic flexibility is kept. The Warburg effect is persistent: a dependency on substrate-level phosphorylation with lost flexibility. On this hypothesis, the acute loop is Crabtree-like. The chronic loop, once remodeling has made it standing architecture, is Warburg-like.

That is not arbitrary. It is path dependence. The anatomy of the scar tells you which loop was left on. The diseases that cluster in the same people are not a coincidence of risk-factor lists. They are what human matching circuits look like after they have been used as standing structure.

The claim must be kept honest. Not every chronic disease begins as a single-cell ATP wattage shortfall. Some start as substrate overflow, some as mechanical strain, some as infection or toxin. The metabolic model stays strong if the claim is this: whatever the first mismatch, biology answers with a short-loop program. If the mismatch persists, that program becomes architecture. The architecture is the scar. The scar then causes new ATP and delivery failure in neighboring systems.

Plaque, stiff artery, failed erection, high intraocular pressure, a glaucomatous field, insulin resistance, some dementia, and the locked glycolytic clone are siblings under that definition. They are not siblings because they all began in the same mitochondrion on the same Tuesday. They are siblings because they are the chronic chapter of matching.

Insulin Resistance Is a Scar of Tolerance

Acute hyperinsulinemia is compensation. The muscle is not taking glucose as it should---mitochondrial inflexibility, ectopic lipid, ROS at the receptor, or an ATP/redox state that makes insulin signaling unwelcome. Insulin rises, shoves substrate somewhere, spares the brain, keeps ATP coming from glycolysis if oxidative phosphorylation will not. For an hour that is adaptive.

Chronic hyperinsulinemia is the loop left on. Receptors down-regulate. Adipose expands. The liver keeps making glucose. The same endothelium that needs coupled eNOS now lives in a high-insulin, high-ROS, high-free-fatty-acid milieu linked to endothelial dysfunction and eNOS uncoupling. The "tolerance" is the scar. You are looking at the same shape as other tolerances: the dose that saved the hour becomes the milieu that ruins the decade.

Insulin resistance therefore belongs next to NO failure, not in a separate metabolic silo. It is another matching hormone asked to run as architecture. The scar then writes the next ones: endothelial energy/redox failure, plaque, stiff pressure, and the brain's own insulin-and-flow matching loops.

Why NO Is Central to Atherosclerosis

Endothelial dysfunction with reduced NO bioavailability is among the earliest events in atherogenesis, detectable before flow-limiting plaque. Risk factors---hyperlipidemia, diabetes, hypertension, smoking, aging, inactivity---share a final common path: oxidative stress that reacts NO with superoxide to form peroxynitrite, depletes tetrahydrobiopterin, and uncouples eNOS so that the enzyme itself produces superoxide. The delivery manager becomes a source of the damage it was meant to prevent.

Physiologic, low-flux, eNOS-derived NO is anti-atherogenic for the reasons given in Act III. Remove it and the lumen becomes adhesive, leaky, prothrombotic, and permissive of smooth-muscle migration. Lipid enters. Monocytes follow. Foam cells form. The conduit that was supposed to serve mitochondrial flux becomes the disease.

There is a dual face, and it must be stated without sentimentality. High-output iNOS, or uncoupled eNOS plus abundant superoxide, generates concentrations of NO and peroxynitrite that nitrate proteins, further uncouple the synthase, and injure mitochondria. Flooding the system with NO donors is therefore not a clean anti-atherosclerotic strategy. Restoring coupled eNOS, reducing the oxidative load that uncouples it, and keeping shear laminar are the metabolic interventions. The same logic that rejects blanket antioxidants in aging applies here: the signal is not the enemy; the inefficient, uncoupled source is.

The plaque itself is the scar. Acute endothelial activation and monocyte entry can be cleanup. Chronic necrotic core, fibrous cap, and calcium are architecture. Once calcified and stiff, the plaque writes the next pressure and flow field. Atherosclerosis is not a random clot. It is the wall's long-term answer to lipid plus low NO plus disturbed shear. That is why NO belongs in the metabolic hypothesis of aging rather than only in the cardiology textbook. Vascular decline is not a separate organ story. It is the progressive inability of the delivery layer to support the ATP generating capacity of the tissues it serves. Plaque is what a failed flux manager leaves behind.

Hypertension as Scar, Not as Successful Compensation

A tempting shortcut is to say that hypertension is the vessel's attempt to compensate for insufficient ATP generation relative to load. The acute exercise data make that shortcut look better than it is. In exercise, pressure rises because flow rises more than resistance falls. In chronic hypertension, resistance is the standing problem.

What is true and EnSurf-compatible:

  • Endothelial ATP and redox failure uncouple eNOS. Superoxide eats NO. The valve that should drop resistance when load rises stays stiff.
  • Chronically high pressure plus oscillatory shear remodel the wall---collagen, less elastin, vascular smooth-muscle hypertrophy. That locks in higher TPR and pulse pressure. Arteriosclerosis (medial stiffening) and atherosclerosis (intimal plaque) are related locks, not identical ones. Stiff conduit arteries raise systolic pressure even when mean resistance is only modestly up.
  • The kidney dominates long-term pressure control; in this model it then resets pressure-natriuresis around the new pressure, and sympathetic and renin--angiotensin tone keep the set point high. That is how a delivery-system failure becomes a standing high-pressure state.

The extra complexity does not weaken the root. It is what a cross-system scar looks like. Kidney, sympathetic nerves, endothelium, and vascular smooth muscle all run matching programs. Chronic endothelial energy and redox failure can start several of them at once. Hypertension is not one location of ATP deficit. It is simultaneous failure of the normal homeostatic operating procedure in every bed that shares the same endothelium and the same renal set-point machinery.

What is not accurate is to say the organism is choosing higher blood pressure so mitochondria get more ATP. The scar is high resistance and a reset kidney. Pressure is the readout. You are not looking at completed compensation. You are looking at the residue of a matching loop that can no longer close, then the remodeling that makes the loop even harder to close.

Training still belongs on the other side of this ledger. High energy flux done as repeated, directed work produces pulsatile laminar shear that protects eNOS. Sedentary low flux plus high pressure does the reverse. The EnSurf variable remains ATP output relative to demand. Hypertension is usually a delivery-system scar that secondarily worsens that ratio.

Mechanosensation makes the point concrete. In mice and endothelial cells, PIEZO1 converts shear into calcium and a cascade that includes ATP release, P2Y2 signaling, and Akt phosphorylation of eNOS, and, over time, shear raises transcription of the enzyme. Disturbed oscillatory shear at bifurcations activates a different program---NF-κB, adhesion molecules, superoxide---and is where plaques begin. The geometry of flow writes the biology of the wall.

Vascular Impotence Is More Than Atherosclerotic Stenosis

Classic "vasculogenic impotence" meant atherosclerotic obstruction of the pudendal--cavernosal arterial tree. That lesion exists. It is not the whole disease.

Penile arteries are smaller than coronary arteries. The same endothelial process that will one day limit coronary flow declares itself first as erectile failure. That is the artery-size hypothesis, and it is why ED is a warning, not a local curiosity. But even that understates the problem.

Erection is an energy-flux event in a specialized vascular bed. In animal studies, nNOS from cavernous nerves initiates the NO pulse and endothelial NO sustains it. Cavernosal smooth muscle relaxes. Sinusoids fill. Veno-occlusion traps blood. The tissue must then maintain tone long enough for the event, which is ATP-expensive work in smooth muscle that has been asked to stay relaxed against a rising intramural pressure.

The acute-versus-chronic grammar is cleaner here than in hypertension.

Acute: arousal → nNOS pulse → eNOS → cGMP → cavernosal relaxation → inflow plus veno-occlusion. Good compensation. Deliver flow against a rising intramural load.

Chronic ATP and redox failure: uncoupled eNOS, ROS, loss of cavernosal smooth-muscle content, fibrosis, venous leak, sometimes plaque. The valve and the sponge can no longer execute the acute act. That is the scar.

Failure can occur at any layer:

  • Endothelial NO--cGMP signaling impaired before any plaque is flow-limiting.
  • Loss of cavernosal smooth-muscle content and fibrosis, so the sponge cannot expand or lock.
  • Veno-occlusive incompetence---"venous leak"---so filling cannot be trapped.
  • Cavernous-nerve injury, which removes the nNOS ignition pulse regardless of arteries.
  • Microvascular and autonomic change.

PDE5 inhibitors work by amplifying residual NO. They do not drill through an atherosclerotic stenosis. They can still succeed when the pipe is only modestly narrowed and some signal remains. They fail when there is no pulse, no muscle, or no occlusion mechanism. Observational associations between PDE5 inhibitor exposure and lower MACE are consistent with a systemic endothelial effect in men who already have some impairment---the same men in whom amplifying cGMP still has a substrate to work on.

Vasculogenic ED is therefore a mixture of endothelial dysfunction, smooth-muscle and veno-occlusive failure, and sometimes macroscopic arterial disease. It is an early, tissue-specific readout of failed energy-flux management in a small, demanding vascular bed. Treating it as "clogged pipes only" misses the metabolic diagnosis and misses the window in which conduit protection still matters for the heart.

Glaucoma: Sage — Glaucoma. The ocular chapters of PDE5 pharmacology: Sage — Cardiology.

PDE5 Inhibitors: Amplifier, Not Source

The pharmacology is straightforward and is too often sold as something else. A PDE5 inhibitor raises the gain on an existing NO--cGMP pulse. If the pulse is present, relaxation lasts longer. If the pulse is absent, the drug is an expensive placebo with a side-effect profile.

Prevention in Healthy Adults, and the EnSurf-Fit Male

Large claims-database studies in men prescribed PDE5 inhibitors---mostly for erectile dysfunction, some for lower urinary tract symptoms---show lower MACE, cardiovascular death, and all-cause mortality, often with an exposure gradient. Some analyses also report less dementia. Princeton IV and related expert statements treat the signal as serious and have described low-dose tadalafil as appropriate in selected men already at elevated atherosclerotic risk. They have not recommended the class as primary prevention for asymptomatic low-risk adults.

The limitations are the ones that always attend this kind of evidence. The data are observational. Men who fill these prescriptions differ in health-seeking, sexual activity, and unmeasured confounders. The populations already had ED or risk factors---that is, some endothelial impairment, some residual signal worth amplifying. There is no large, long randomized trial of daily PDE5 inhibition for primary prevention in healthy, high-flux men. These are prescription drugs. Safety in labeled, physician-guided use is good. Chronic use still costs headache, reflux, rare reported NAION and hearing events, a nitrate interaction that matters the day a coronary plaque declares itself, and money.

An EnSurf-fit adult male already runs the conditions that write eNOS: repeated laminar shear from training, coupled enzyme, adequate BH4, lower ambient superoxide, intact glycocalyx, circadian and fuel inputs that keep mitochondria from leaking the oxidants that uncouple the synthase. In this model, his NO--cGMP set point is high because the source is healthy, and adding PDE5 blockade raises gain on a signal that is not the constraint. Possible small effects remain---a few millimeters of mercury, a bit more microvascular recruitment, anti-fibrotic PKG tone that matters more when stiffness is already present. Diminishing returns are the honest prediction. The observational mortality benefit lives where the pathway is impaired. In a high-flux male the same tablet is more likely to buy side effects than a new energy-flux architecture.

The EnSurf order does not change. Training is still one of the strongest eNOS and shear stimuli available without a prescription. Fuel that mitochondria can oxidize cleanly reduces the oxidative load that uncouples the enzyme. Circadian alignment supports the daily transcription and quality-control rhythms of both mitochondria and endothelium. Nitrate-rich plants can feed the nitrate--nitrite--NO enterosalivary loop as an adjunct, not as a substitute for coupled eNOS. Conditioning and hormesis raise the threshold at which cells choose apoptosis or senescence when flux is transiently stressed. A PDE5 inhibitor belongs in the stack when there is ED, LUTS, or documented intermediate vascular risk---on-label use with a systemic bonus---not as a default longevity tablet for a man whose engine and pipes are already matching load.

Cancer, Dementia, and the Rest of the Scar Family

The companion hypothesis of cancer already contains this chapter. Glycolytic rescue is an ancestral survival program for when oxidative ATP cannot meet demand. If the mismatch persists, selection locks clones that live on that program. The Warburg phenotype is a metabolic scar that has become a lineage. It is not a mutation lottery first. It is a matching loop---ferment when the mitochondrion cannot---used as standing architecture. In the author’s reading, the same two steps appear inside organs whose principal work is energy-intensive: clear-cell renal cell carcinoma in the kidney and hepatocellular carcinoma in the liver.

Dementia is not one scar. The slice that is chronic hypoperfusion, endothelial NO loss, insulin resistance in brain, failed neurovascular coupling (nNOS and eNOS again), and mitochondrial failure in high-cost neurons is the same grammar. Networks that cannot be supplied are pruned. The atrophy pattern is the scar, not a lottery of plaques only. Plaques and tangles can be part of the architecture. They are not required to make the matching claim.

Field loss, plaque, cuff pressure, erection that will not hold, a brain that cannot couple flow to thought, a tumor that lives on glycolysis, a muscle that no longer listens to insulin: these are not random events that happen to share risk factors. They are what it looks like when acute matching has been the default state long enough to remodel the tissue that was supposed to turn the signal off.

Unifying Power and Parsimony

The phenomena collected in this essay are usually housed in separate chapters: cardiovascular physiology, andrology, ophthalmology, mitochondrial biochemistry, preventive cardiology, endocrinology, oncology. They reduce to one relationship with two timescales.

ATP output relative to demand is the measured variable of the EnSurf hypotheses. Nitric oxide is the short-range manager that tries to keep that ratio livable at the scale of an arteriole, a Schlemm's canal, a cavernosal sinusoid, and a mitochondrion. Shear writes the capacity of the manager. Superoxide and uncoupling destroy it. On the acute timescale the manager raises conductance and rations oxygen. On the chronic timescale the failed or never-cleared loop becomes architecture.

Plaque is the scar of its absence in the wall. A stiff artery and a reset kidney are the scar in the pressure circuit. Erectile failure is an early small-vessel confession. Cytochrome oxidase inhibition is the manager rationing the terminal acceptor so delivery is not wasted at the first organelle. PDE5 inhibitors are gain knobs on a pulse the manager must still produce. Blue vision is an off-target enzyme in the retina. NAION is a rare ischemic event in a crowded optic disc. A glaucomatous field is the map of axons that lived too long in the worst pixels of strain and perfusion. Insulin resistance is tolerance become milieu. A glycolytic tumor is rescue become lineage.

This is more parsimonious than treating each as an independent disease. It is more comprehensive because it explains why exercise, which looks like a "lifestyle" recommendation, is in fact an endothelial gene-expression therapy and a mitochondrial biogenesis therapy at once---and why the same man collects plaque, pressure, glucose intolerance, and a suspicious disc. It is more coherent with the metabolic hypotheses of aging and cancer: when delivery and matching fail, tissues drift toward glycolytic rescue, inflammation, senescence, and, in some niches, the fermentative programs that selection then locks in as malignancy.

The hypothesis is falsifiable. If NO were only a vasodilator, restoring coupled eNOS or amplifying cGMP would change blood pressure and erection without changing mitochondrial matching, plaque initiation, conventional outflow facility, or the timing of ED relative to coronary disease. If CCO inhibition were only toxicity, physiologic NO would worsen rather than extend oxygen gradients. If chronic hypertension were successful ATP compensation, raising pressure would raise tissue ATP; it does not, in any simple way, in the essential hypertensive. If PDE5 inhibitors were primary prevention for high-flux men, randomized trials in that population would show event reductions comparable to the observational ED cohorts. The existing literature already leans the other way on that last prediction.

Therapeutic Implications Inside EnSurf

If nitric oxide is an energy-flux manager, and if the chronic diseases around it are scars of matching left on, therapy prioritizes the conditions that keep the manager coupled, keep the loops pulsed rather than standing, and keep the engine supplied.

Fuel. Substrates mitochondria can oxidize cleanly reduce electron leak and the superoxide that uncouples eNOS. The nested symbionts---mitochondrion and gut community---still prefer the fuels they were trained on. In this model, chronic hyperinsulinemic and seed-oil-dominant patterns that impair mitochondrial handling also impair the redox environment the synthase requires. They are how the insulin loop is left on.

Circadian alignment. eNOS transcription, BH4 synthesis, and mitochondrial quality control are cyclic. Morning light, consistent sleep, and a dim evening are not wellness ornaments. They are timing cues for the same dynamic process that converts food electrons into ATP. Nocturnal pressure dips and nocturnal intraocular pressure peaks meet the disc at night; sleep and the timing of antihypertensives are not footnotes.

Strength and conditioning. Dynamic resistance and aerobic work are the shear and load stimuli that phosphorylate eNOS today and write more of it tomorrow. They raise tissue mitochondrial volume. Grip strength and VO2 max remain practical surrogates of fitness. In this model, hormetic conditioning resets apoptosis thresholds so that cells under transient flux stress repair rather than exit. This is the difference between acute matching and chronic operating procedure, trained on purpose.

These interventions do not replace indicated pharmacologic therapy; they may address the upstream mismatch that makes those therapies necessary and reduce the probability that acute Crabtree-like compensations lock into Warburg architecture.

Do not start with the gain knob. PDE5 inhibition, nitrate donors, and even dietary nitrate are adjuncts. They do not replace coupled endothelial production or mitochondrial density. In a man with ED or intermediate plaque burden they may be useful tools. PDE5 drugs are prescription medicines for specific conditions, not a prevention tool for healthy men; whether to use one is a physician's call, weighed against rare reported NAION, nitrate future-use, and the absence of randomized prevention data. An NO-donating glaucoma drop is a local gain knob on a rusted barostat---on-label, targeted, and not a license to flood the nerve head with inducible NO.

Protect the conduit by protecting the source. Anti-atherogenic practice is endothelial-coupling practice: keep shear laminar, keep BH4 available, keep superoxide from becoming the default fate of electrons that should have reached cytochrome oxidase. The same sentence is anti-glaucomatous practice at Schlemm's canal and anti-impotence practice in the cavernosum.

Conclusion

Nitric oxide is not primarily a lifestyle molecule, an erectile drug target, or a footnote in plaque charts. It is the gas with which the organism matches blood flow---and aqueous outflow---to mitochondrial demand, rations oxygen so the gradient reaches deep tissue, and keeps the conduit from becoming the disease. The remainder of vascular and ocular biology---smooth-muscle tone, shear transcription, uncoupling, atherosclerosis, vasculogenic erectile failure, the modest systemic signal of PDE5 inhibitors, the blue tinge, a rare reported ischemic event at a crowded optic disc (NAION), the trabecular barostat, the strained lamina, the arcuate field---organizes around that job.

Aging, in the companion hypothesis, is progressive loss of ATP generating capacity. Cancer, in its companion, is an energy crisis that selects for glycolytic rescue. Fuel, in its companion, is whether the nested symbionts are given substrates they can oxidize and ferment without assaulting their membranes. Nitric oxide is the manager that stands between those intracellular stories and the blood, and the aqueous, that must serve them.

When the manager is coupled and the toll-keeper is busy, high energy flux is sustainable and matching stays pulsed. When the manager fails, delivery fails, matching fails, and the loop is left on. The pipe scars. The pressure circuit scars. The sponge scars. The meshwork stiffens. The field scars. The clone locks. Insulin stops being a pulse and becomes a climate. These are not decorations on the metabolic model. They are the model's chronic chapter.

Prevention and treatment therefore begin where the other EnSurf essays begin: real food, circadian coherence, and work that writes shear and mitochondrial volume so the acute loop can turn off. Amplifiers of cGMP have a place when the pulse is weak. They are not a substitute for restoring the pulse, and they are not a treatment for a scar that has already become architecture---except where, as in conventional outflow, the architecture is still a muscle-like tissue that can relax. As endothelial phenotyping, OCT imaging of the disc, and tissue-level flux measurement mature, this hypothesis can be tested where it claims to be strongest---at the junction of delivery, consumption, and the simple toll-keeper on which the rest of biology still turns.

This essay synthesizes published mechanisms in nitric oxide biology, vascular physiology, mitochondrial respiration, atherosclerosis, erectile hemodynamics, PDE5 pharmacology, aqueous outflow, optic-nerve-head perfusion, and metabolic set-point biology as of 2026. It is a hypothesis, not medical advice. Individual evaluation by a qualified physician remains essential.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 29, 2026.

References

  1. Watt IN, Montgomery MG, Runswick MJ, et al., 2010. Bioenergetic cost of making an adenosine triphosphate molecule in animal mitochondria. Proceedings of the National Academy of Sciences USA 107(39):16823-16827. doi:10.1073/pnas.1011099107
  2. Förstermann U, Sessa WC, 2012. Nitric oxide synthases: regulation and function. European Heart Journal 33(7):829-837. doi:10.1093/eurheartj/ehr304
  3. Davignon J, Ganz P, 2004. Role of endothelial dysfunction in atherosclerosis. Circulation 109(23 Suppl 1):III27-III32. doi:10.1161/01.CIR.0000131515.03336.f8
  4. Montorsi F, Briganti A, Salonia A, et al., 2003. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. European Urology 44(3):360-364. doi:10.1016/s0302-2838(03)00305-1
  5. Chiu JJ, Chien S, 2011. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiological Reviews 91(1):327-387. doi:10.1152/physrev.00047.2009
  6. Wang S, Chennupati R, Kaur H, et al., 2016. Endothelial cation channel PIEZO1 controls blood pressure by mediating flow-induced ATP release. Journal of Clinical Investigation 126(12):4527-4536. doi:10.1172/JCI87343
  7. SenBanerjee S, Lin Z, Atkins GB, et al., 2004. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. Journal of Experimental Medicine 199(10):1305-1315. doi:10.1084/jem.20031132
  8. Sarti P, Forte E, Mastronicola D, et al., 2012. Cytochrome c oxidase and nitric oxide in action: molecular mechanisms and pathophysiological implications. Biochimica et Biophysica Acta 1817(4):610-619. doi:10.1016/j.bbabio.2011.09.002
  9. Brown GC, Cooper CE, 1994. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Letters 356(2-3):295-298. doi:10.1016/0014-5793(94)01290-3
  10. Thomas DD, Liu X, Kantrow SP, et al., 2001. The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2. Proceedings of the National Academy of Sciences USA 98(1):355-360. doi:10.1073/pnas.98.1.355
  11. Brown GC, 1999. Nitric oxide and mitochondrial respiration. Biochimica et Biophysica Acta 1411(2-3):351-369. doi:10.1016/s0005-2728(99)00025-0
  12. De Caterina R, Libby P, Peng HB, et al., 1995. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. Journal of Clinical Investigation 96(1):60-68. doi:10.1172/JCI118074
  13. Kobzik L, Reid MB, Bredt DS, et al., 1994. Nitric oxide in skeletal muscle. Nature 372(6506):546-548. doi:10.1038/372546a0
  14. Joyner MJ, Casey DP, 2015. Regulation of increased blood flow (hyperemia) to muscles during exercise: a hierarchy of competing physiological needs. Physiological Reviews 95(2):549-601. doi:10.1152/physrev.00035.2013
  15. Halliwill JR, 2001. Mechanisms and clinical implications of post-exercise hypotension in humans. Exercise and Sport Sciences Reviews 29(2):65-70. doi:10.1097/00003677-200104000-00005
  16. Hambrecht R, Adams V, Erbs S, et al., 2003. Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation 107(25):3152-3158. doi:10.1161/01.CIR.0000074229.93804.5C
  17. Lund-Johansen P, 1991. Twenty-year follow-up of hemodynamics in essential hypertension during rest and exercise. Hypertension 18(5 Suppl):III54-III61. doi:10.1161/01.hyp.18.5_suppl.iii54
  18. Kim JA, Montagnani M, Koh KK, et al., 2006. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113(15):1888-1904. doi:10.1161/CIRCULATIONAHA.105.563213
  19. Förstermann U, Münzel T, 2006. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113(13):1708-1714. doi:10.1161/CIRCULATIONAHA.105.602532
  20. Guyton AC, 1991. Blood pressure control--special role of the kidneys and body fluids. Science 252(5014):1813-1816. doi:10.1126/science.2063193
  21. Montorsi P, Ravagnani PM, Galli S, et al., 2005. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. American Journal of Cardiology 96(12B):19M-23M. doi:10.1016/j.amjcard.2005.07.006
  22. Hurt KJ, Musicki B, Palese MA, et al., 2002. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proceedings of the National Academy of Sciences USA 99(6):4061-4066. doi:10.1073/pnas.052712499
  23. Ashpole NE, Overby DR, Ethier CR, et al., 2014. Shear stress-triggered nitric oxide release from Schlemm's canal cells. Investigative Ophthalmology & Visual Science 55(12):8067-8076. doi:10.1167/iovs.14-14722
  24. Stamer WD, Lei Y, Boussommier-Calleja A, et al., 2011. eNOS, a pressure-dependent regulator of intraocular pressure. Investigative Ophthalmology & Visual Science 52(13):9438-9444. doi:10.1167/iovs.11-7839
  25. Kang JH, Wiggs JL, Rosner BA, et al., 2010. Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with sex and postmenopausal hormone use. Investigative Ophthalmology & Visual Science 51(2):971-979. doi:10.1167/iovs.09-4266
  26. Nathanson JA, McKee M, 1995. Alterations of ocular nitric oxide synthase in human glaucoma. Investigative Ophthalmology & Visual Science 36(9):1774-1784. PubMed 7543463
  27. Cavet ME, DeCory HH, 2018. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies. Journal of Ocular Pharmacology and Therapeutics 34(1-2):52-60. doi:10.1089/jop.2016.0188
  28. Burgoyne CF, Downs JC, Bellezza AJ, et al., 2005. The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Progress in Retinal and Eye Research 24(1):39-73. doi:10.1016/j.preteyeres.2004.06.001
  29. Hayreh SS, Zimmerman MB, Podhajsky P, et al., 1994. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. American Journal of Ophthalmology 117(5):603-624. doi:10.1016/s0002-9394(14)70067-4
  30. Neufeld AH, Hernandez MR, Gonzalez M, 1997. Nitric oxide synthase in the human glaucomatous optic nerve head. Archives of Ophthalmology 115(4):497-503. doi:10.1001/archopht.1997.01100150499009
  31. Kang JH, Willett WC, Rosner BA, et al., 2016. Association of Dietary Nitrate Intake With Primary Open-Angle Glaucoma: A Prospective Analysis From the Nurses' Health Study and Health Professionals Follow-up Study. JAMA Ophthalmology 134(3):294-303. doi:10.1001/jamaophthalmol.2015.5601
  32. Bischoff E, 2004. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. International Journal of Impotence Research 16 Suppl 1:S11-S14. doi:10.1038/sj.ijir.3901208
  33. Beck RW, Servais GE, Hayreh SS, 1987. Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology 94(11):1503-1508. PubMed 3684223
  34. Campbell UB, Walker AM, Gaffney M, et al., 2015. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. Journal of Sexual Medicine 12(1):139-151. doi:10.1111/jsm.12726
  35. Hattenhauer MG, Leavitt JA, Hodge DO, et al., 1997. Incidence of nonarteritic anterior ischemic optic neuropathy. American Journal of Ophthalmology 123(1):103-107. doi:10.1016/s0002-9394(14)70999-7
  36. Banach M, Serban C, Ursoniu S, et al., 2015. Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials. Pharmacological Research 99:329-336. doi:10.1016/j.phrs.2015.07.008
  37. Neeland IJ, Linge J, Birkenfeld AL, 2024. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism 26 Suppl 4:16-27. doi:10.1111/dom.15728
  38. Antoniades C, Bakogiannis C, Leeson P, et al., 2011. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 124(3):335-345. doi:10.1161/CIRCULATIONAHA.110.985150
  39. Chai W, Dong Z, Wang N, et al., 2012. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61(4):888-896. doi:10.2337/db11-1073
  40. Hebsgaard JB, Pyke C, Yildirim E, et al., 2018. Glucagon-like peptide-1 receptor expression in the human eye. Diabetes, Obesity and Metabolism 20(9):2304-2308. doi:10.1111/dom.13339
  41. Marso SP, Bain SC, Consoli A, et al., 2016. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 375(19):1834-1844. doi:10.1056/NEJMoa1607141
  42. Diabetes Control and Complications Trial Research Group, 1998. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Archives of Ophthalmology 116(7):874-886. doi:10.1001/archopht.116.7.874
  43. Rubino D, Abrahamsson N, Davies M, et al., 2021. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 325(14):1414-1425. doi:10.1001/jama.2021.3224
  44. She J, Tuerhongjiang G, Guo M, et al., 2024. Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner. Cell Metabolism 36(2):408-421.e5. doi:10.1016/j.cmet.2023.12.027
  45. Heberer K, Bress AP, Cogill S, et al., 2026. New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes. JAMA Ophthalmology 144(3):259-264. doi:10.1001/jamaophthalmol.2025.6262
  46. Simonsen E, Lund LC, Ernst MT, et al., 2025. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study. Diabetes, Obesity and Metabolism 27(6):3094-3103. doi:10.1111/dom.16316
  47. Cai CX, Hribar M, Baxter S, et al., 2025. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmology 143(4):304-314. doi:10.1001/jamaophthalmol.2024.6555
  48. Hathaway JT, Shah MP, Hathaway DB, et al., 2024. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology 142(8):732-739. doi:10.1001/jamaophthalmol.2024.2296
  49. Andersson DP, Trolle Lagerros Y, Grotta A, et al., 2017. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart 103(16):1264-1270. doi:10.1136/heartjnl-2016-310746
  50. Adesuyan M, Jani YH, Alsugeir D, et al., 2024. Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study. Neurology 102(4):e209131. doi:10.1212/WNL.0000000000209131
  51. Kloner RA, Burnett AL, Miner M, et al., 2024. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health. Journal of Sexual Medicine 21(2):90-116. doi:10.1093/jsxmed/qdad163
  52. Lundberg JO, Weitzberg E, Gladwin MT, 2008. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nature Reviews Drug Discovery 7(2):156-167. doi:10.1038/nrd2466
  53. Iadecola C, 2017. The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron 96(1):17-42. doi:10.1016/j.neuron.2017.07.030
  54. Liu JH, Kripke DF, Hoffman RE, et al., 1998. Nocturnal elevation of intraocular pressure in young adults. Investigative Ophthalmology & Visual Science 39(13):2707-2712. PubMed 9856781
  55. Banach M, Serban C, Sahebkar A, et al., 2015. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clinic Proceedings 90(1):24-34. doi:10.1016/j.mayocp.2014.08.021
  56. Berdahl JP, Allingham RR, Johnson DH, 2008. Cerebrospinal fluid pressure is decreased in primary open-angle glaucoma. Ophthalmology 115(5):763-768. doi:10.1016/j.ophtha.2008.01.013
  57. Ren R, Jonas JB, Tian G, et al., 2010. Cerebrospinal fluid pressure in glaucoma. Ophthalmology 117(2):259-266. doi:10.1016/j.ophtha.2009.06.058
  58. Laties AM, 2009. Vision disorders and phosphodiesterase type 5 inhibitors. Drug Safety 32(1):1-18. doi:10.2165/00002018-200932010-00001
  59. Hayreh SS, Podhajsky PA, Zimmerman B, 1997. Nonarteritic anterior ischemic optic neuropathy: time of onset of visual loss. American Journal of Ophthalmology 124(5):641-647. doi:10.1016/s0002-9394(14)70902-x
  60. Stein JD, Newman-Casey PA, Talwar N, et al., 2012. The relationship between statin use and open-angle glaucoma. Ophthalmology 119(10):2074-2081. doi:10.1016/j.ophtha.2012.04.029

Related: Sage — Cardiology · Sage — Signals · Sage — Eye.

See the notice at the top of this page. Working hypothesis, not medical advice.